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A B S T R A C T
Objective: The Risk of Malignancy Index (RMI) is a simple scoring system to standardize and improve the
preoperative evaluation of adnexal masses. Since 1990, three versions of the RMI have been validated in
different clinical studies. Recently, a fourth version of the RMI (RMI-4) was introduced that includes
tumor size as an additional parameter. The aim of this study was to validate the ability of RMI-4 to
discriminate between non-invasive lesions and invasive malignant adnexal masses, and to compare its
performance with RMI-3.
Study design: Women scheduled for surgery for an adnexal mass between 2005 and 2009 in 11 hospitals
were included. Ultrasonographic characteristics, menopausal status and serum CA 125 level were
registered preoperatively, and combined into the RMI. The performances of RMI-3 and RMI-4 were
assessed and statistically tested for differences.
Results: A total of 643 patients were included: 469 benign, 73 borderline and 101 malignant tumors. The
RMI-3 had a sensitivity of 76%, speciﬁcity of 82%, positive and negative predictive values (PPV and NPV) of
45% and 95%, and an accuracy of 81%. The RMI-4 had a sensitivity of 74%, speciﬁcity of 79%, PPV of 40%,
NPV of 94%, and an accuracy of 78%. The accuracy of RMI-3 was signiﬁcantly higher than the accuracy of
RMI-4 (p = .001). Both models had an area under the curve of 0.86.
Conclusion: Both RMI-3 and RMI-4 were able to discriminate between non-invasive lesions and invasive
malignant adnexal masses, with similar performances. Including tumor size in the RMI does not improve
its performance.
 2011 Elsevier Ireland Ltd.  
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Open access under the Elsevier OA license. 1. Introduction
The discriminative preoperative evaluation of adnexal masses is
rather complicated. A variety of diagnostic procedures has been
used, leading to a wide range of variables which can result in an
inaccurate interpretation of the nature of the adnexal mass. In view
of treatment of ovarian cysts, the assessment between benign and
malignant needs to be performed as accurate as possible. To
standardize and improve the preoperative evaluation, Jacobs et al.
[1] developed the Risk of Malignancy Index (RMI), which is a
simpliﬁcation of a formula found by logistic regression analysis. The* Corresponding author at: Radboud University Nijmegen Medical Centre,
Department of Obstetrics and Gynecology (791), P.O. Box 9101, 6500 HB Nijmegen,
The Netherlands. Tel.: +31 24 361 64 53; fax: +31 24 366 85 97.
E-mail address: S.vandenAkker@obgyn.umcn.nl (Petronella A.J. van den Akker).
0301-2115   2011 Elsevier Ireland Ltd. 
doi:10.1016/j.ejogrb.2011.07.035
Open access under the Elsevier OA license. RMI was the ﬁrst diagnostic model that combined demographic,
sonographic and biochemical data in the assessment of patients with
adnexal masses. The main advantage of this method compared with
other diagnostic models is that the RMI is a simple scoring system
that can be applied directly into clinical practice without the
introduction of expensive or difﬁcult tools. The original RMI is
known as RMI-1. The RMI has been modiﬁed by Tingulstad et al. in
1996 (RMI-2) [2] and again in 1999 (RMI-3) [3]. The difference
between these three measurement tools lies in the different scoring
of ultrasound characteristics and menopausal status. The three
versions of the RMI have been validated retrospectively and
prospectively in various clinical studies [1–15] where a cutoff value
of 200 showed the best discrimination between benign and
malignant adnexal masses, with high sensitivity and speciﬁcity
levels (sensitivity 51–90%, speciﬁcity 51–97%).
Recently, a fourth RMI was introduced by Yamamoto et al. [16]
which includes tumor size as an additional parameter. They found
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of 200 in the three previous RMIs. When they compared the RMI-4
in a retrospective study with 253 cases with the previous RMIs, an
improved performance at a cutoff level of 450 was found, with an
accuracy of 90%. The RMI-4 still needs to be validated prospectively
and in different institutions, to assess external validity.
The aim of the present study was to validate the ability of RMI-4
to discriminate between non-invasive lesions and invasive
malignant adnexal masses in daily clinical practice, and to compare
its performance with RMI-3.
2. Materials and methods
This study was conducted between January 2005 and Septem-
ber 2009 in the Radboud University Nijmegen Medical Centre
(RUNMC), a third line regional referral hospital, and in 10
cooperating hospitals in the east of The Netherlands. The study
was approved by the medical ethics committee of the Radboud
University Nijmegen Medical Centre. The study included 643
women admitted for surgical procedure for an adnexal mass. We
have previously published on the RMI-3 in a subgroup of the
present study population [15]. Ultrasound was performed
transvaginally combined with abdominal ultrasound when need-
ed, by experienced gynecological oncologists, general gynecolo-
gists, or registrars in gynecology. Serum samples were analysed for
CA 125 as part of routine preoperative assessment, and meno-
pausal status was registered. Based on the data obtained, the RMI-3
was calculated prospectively as the multiplied value of the
ultrasound score (U), menopausal status (M) and serum CA 125
level as follows:
RMI-3 [3] = U  M  CA 125. Multilocularity, solid areas,
bilaterality, ascites and intra-abdominal metastases score one
point each. A total of 2 or more points was recalculated into U = 3,
fewer than 2 points into U = 1. Postmenopausal status is deﬁned as
more than 1 year of amenorrhea, or age 50 years or older among
women who had prior hysterectomies, and scores M = 3;
premenopausal status scores M = 1. Serum CA 125 (U/mL) was
entered directly into the equation.
Based on the obtained data, RMI-4 was calculated retrospec-
tively as follows:
RMI-4 [16] = U  M  S  CA 125. A total ultrasound score of 0
or 1 was recalculated into U = 1, and a score of 2 into U = 4.
Premenopausal status scores M = 1 and postmenopausal status
scores M = 4. The tumor size was obtained from the pathology
report. A tumor size (single greatest diameter) of <7 cm was
recalculated into S = 1, and 7 cm into S = 2, as introduced by
Yamamoto et al. [16]. The serum CA 125 (U/mL) was applied
directly to the calculation.
Final diagnoses of included patients were based on the
histopathological examination of surgical specimens. Patients that
were diagnosed with non-gynecological malignancies were
excluded from the study.
The RMI was merely registered and not applied in a
standardized manner in the further planning of care. Based on
the clinical impression by the gynecologist in the local hospital it
was decided whether a gynecological oncologist should be
involved in the surgical treatment. This clinical impression was
based on routine preoperative assessment, consisting of physical
examination, testing of serum samples, and ultrasound examina-
tion. The local gynecologists varied in levels of expertise, from
gynecologists specialised in oncology to general gynecologists.
Statistical analyses were performed using the Statistical
Packages for the Social Sciences Version 16.0.1 (SPSS Inc., Chicago,
IL). The sensitivity, speciﬁcity, positive and negative predictive
values, and accuracy of RMI-3 and RMI-4 were calculated.
Borderline malignancies were allocated to the non-invasive groupin all analyses. Comparison between patients with non-invasive
(benign and borderline) lesions and invasive malignancies was
performed using the Mann–Whitney U test for age and serum CA
125 level, the Pearson x2 test for menopausal status and tumor size
and the Kruskal–Wallis test for ultrasound score. A receiver
operating characteristic (ROC) curve was created to show the
relation between sensitivity and speciﬁcity of both RMI-3 and RMI-
4 in the discrimination between non-invasive lesions and invasive
malignancies, and an area under the curve (AUC) was calculated for
both models. The McNemar’s test was used to test the difference in
performances between RMI-3 and RMI-4. The cutoff level was set
at 200 for RMI-3 and 450 for RMI-4 to be able to compare the
results with the study of Yamamoto et al. [16]. A p-value .05 was
considered as statistically signiﬁcant.
3. Results
A total of 643 patients was included in the study, of whom 469
(73%) were diagnosed with benign ovarian cysts, 73 patients (11%)
with borderline malignancies, and 101 patients (16%) with
malignant diseases. The distribution of age, menopausal status,
ultrasound score, tumor size and serum CA 125 level in the non-
invasive and invasive groups was as shown in Table 1. Statistically
signiﬁcant differences between the two groups were observed for
all these variables. The histopathological diagnoses are listed in
Table 2. The majority of non-invasive gynecological conditions
included mucinous cystadenomas (n = 118) and serous cystade-
nomas (n = 86). Histopathological diagnoses in invasive malignant
diseases were mainly serous cystadenocarcinomas (n = 41).
The performances of the RMI-3 and RMI-4 at different cutoff
levels are presented in Table 3. At a cutoff level of 200, the RMI-3
gave a sensitivity of 76% and a speciﬁcity of 82%. Positive and
negative predictive values at that cutoff level were 45% and 95%,
respectively. The accuracy was 81%. The RMI-4 gave, at a cutoff
level of 450, a sensitivity of 74% and a speciﬁcity of 79%. Positive
and negative predictive values at that cutoff level were 40% and
94%, respectively. The accuracy was 78%. The diagnostic perfor-
mances of both RMI-3 and RMI-4 are illustrated in Fig. 1. A
comparison of the accuracy levels of the two indices showed that
RMI-3 at a cutoff level of 200 was signiﬁcantly better in predicting
invasive malignancy than RMI-4 at a cutoff level of 450 (p = .001).
Both models had an area under the curve of 0.86.
4. Comment
This study has conﬁrmed that both RMI-3 and RMI-4 were able
to discriminate between non-invasive lesions and invasive
malignant masses. The RMI-4 tested on a new population of
women with adnexal masses showed lower sensitivity and
speciﬁcity levels compared with the original report [16].
External validation of proposed models often results in a
decreased performance compared to the performance that is
reported initially [8]. Therefore, external validation of a prediction
model is essential before introduction into clinical practice. In this
new population both RMI-3 and RMI-4 were able to discriminate
between non-invasive lesions and invasive malignant adnexal
masses, with similar performances. Although the accuracy was
higher in RMI-4, the similar AUC and overlappig ROC curves indicate
that the differences in performances are not statistically signiﬁcant.
We have chosen to use the RMI-3 [3] over the original RMI [1] or
RMI-2 [2]. The reason for eliminating RMI-1 is that it gives an
ultrasound score (U) of 0 when none of the ultrasound features
were present. This results in an RMI of 0 regardless of the CA 125
level, whereas we consider the CA 125 level as an important
parameter of the RMI. CA 125 level does contribute in both RMI-2
Table 2
Distribution of histopathological diagnoses.
n %
Non-invasive lesions (n = 542)
Mucinous cystadenomas 118 22
Serous cystadenomas 86 16
Other cystadenomas 14 3
Simple cysts 66 12
Fibroma 57 11
Dermoids 49 9
Endometriotic cysts 40 7
Mucinous borderline 40 7
Serous borderline 29 5
Others 43 8
Invasive malignancies (n = 101)
Serous cystadenocarcinomas 41 40
Mucinous cystadenocarcinomas 10 10
Endometrioid adenocarcinomas 12 12
Undifferentiated adenocarcinomas 15 15
Clear cell carcinomas 14 14
Carcinosarcomas 3 3
Granulosa cell tumors 3 3
Others 3 3
Table 1
Distribution of age, menopausal status, ultrasound score, tumor size and serum CA 125 levels in 643 patients with no non-invasive lesions (n = 542) and invasive malignant
(n = 101) adnexal masses.
Non-invasive lesions (n = 542) Invasive malignancies (n = 101) Signiﬁcance level (p)
Age (years)
Median (range) 55 (13–93) 60 (24–85) .008b
Postmenopausal
n (%) 327 (60%) 73 (72%) .023c
Ultrasound scorea .000d
0
n (%) 129 (24%) 2 (2%)
1
n (%) 210 (39%) 19 (19%)
2–5
n (%) 203 (37%) 80 (79%)
Tumor size .000c
<7 cm
n (%) 204 (38%) 18 (18%)
7 cm
n (%) 338 (62%) 83 (82%)
Serum CA 125 (U/mL)
Median (range) 18 (2–2914) 153 (7–7800) .000b
a Ultrasounds were scored one point for each of the following characteristics: multilocularity, solid areas, bilaterality, ascites and intra-abdominal metastases.
b Mann–Whitney U test.
c Pearson x2 test.
d Kruskal–Wallis test.
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evaluated more extensively than RMI-2.
Yamamoto et al. [16] have allocated borderline malignancies to
the malignant group, whereas we chose to allocate the borderline
tumors to the benign group. The primary goal for developing the
RMI is the accurate referral of patients with invasive malignant
diseases to gynecological oncologists. Although some borderlineTable 3
Performances of RMI-3 and RMI-4a at different cutoff levels.
Cutoff Sensitivity (%) Speciﬁcity (%) 
RMI-3 RMI-4 RMI-3 RMI-4 RMI-3 RMI-4 
100 350 81 76 68 75 
120 400 78 75 76 77 
200 450 76 74 82 79 
250 500 72 73 86 81 
300 550 68 73 87 82 
a RMI = Risk of Malignancy Index.
b PPV = positive predictive value.
c NPV = negative predictive value.malignancies with invasive implants may require signiﬁcant
gynecological oncological debulking, more than 90% of cases are
stage I tumors and most cases behave in a benign fashion [10].
Women with these borderline malignancies do not necessarily
have to undergo aggressive surgical treatment by a gynecological
oncologist to optimize their survival chances.
This difference in allocation of the borderline tumors however,
does not explain the different results between the two studies.
When we confer the borderline malignancies as malignant in our
dataset, the accuracy of RMI-3 and RMI-4 detoriate to 77% and 76%,
respectively. RMI-3 still performs better than RMI-4, but the
difference is not statistically signiﬁcant anymore.
Yamamoto et al. [16] have measured tumor size by ultrasound
for each patient, whereas we have extracted this information from
the pathology report. In daily clinical practice ultrasound would be
used, because this is the only parameter on size that is available
preoperatively. Although there is no evidence in literature,
measurements by ultrasound and by pathology report are
expected to be highly correlated. By applying the RMI-4
retrospectively on our dataset we were able to rapidly produce
an external validation on the RMI-4 in a high number of patients.
Future analysis in a prospective study may however still be needed
to validate the RMI-4 as a new tool.
The additional value of tumor size in predicting ovarian
malignancy is debatable. Tumor size is not considered an
independent predictor of malignancy in ovarian tumors in
literature. Recently, McDonald et al. [17] have assessed several
tumor variables for their correlation with malignancy. Tumor size
with a cutoff level of 10 cm was statistically related to the risk ofPPVb (%) NPVc (%) Accuracy (%)
RMI-3 RMI-4 RMI-3 RMI-4 RMI-3 RMI-4
32 36 95 94 70 75
38 37 95 94 76 76
45 40 95 94 81 78
49 41 94 94 84 79
50 43 94 94 84 81
Fig. 1. Receiver operating characteristic curves of the Risk of Malignancy Index-3
and Risk of Malignancy. Index-4 showing the relation between sensitivity and
speciﬁcity in the discrimination between non-invasive lesions and invasive
malignancies. Footnote: RMI: Risk of Malignancy Index. The area under the curve
is 0.86 for RMI-3 and 0.86 for RMI-4.
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after a multivariable analysis. Using the cutoff level of 10 cm for
the tumor size variable did not improve the performance of RMI-4
in our study population. Unfortunately, Yamamoto et al. did not
explain their decision to add tumor size in the RMI. We do not
know if they have performed a multivariable analysis to establish
that tumor size is an independent predictor of malignancy. Why
they have dichotomised the tumor size variable with a cutoff level
of 7 cm is also not known. In our study population, the majority of
patients with non-invasive lesions (62%) had a tumor size greater
than 7 cm. In case the tumor size is included in the RMI, all these
women with benign lesions end with a doubled RMI score
compared with the situation where the tumor size was not
included in the RMI.
In conclusion, this external validation showed that RMI-3 and
RMI-4 perform similar in predicting invasive malignancy. Our
ﬁndings have reconﬁrmed the ability of the RMI to discriminate
between non-invasive lesions and invasive malignant masses. At
this moment, we do not see any advantage in introducing an
adapted version of the RMI that includes tumor size in the
preoperative assessment of adnexal masses.Conﬂict of interest statement
The authors do not report any potential conﬂicts of interest.
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